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The clinical implications of early and late endothelial progenitor cells (EPCs) in coronary artery disease (CAD) remain unclear. We
investigated endothelial dysfunction inCADby simultaneously examining early and late EPC colony formation and gene expression
of specific surface markers in EPCs. EPCs were extracted from a total of 83 subjects with (𝑛 = 47) and without (𝑛 = 36) CAD.
Early and late EPC colonies were formed frommononuclear cells extracted from peripheral blood. We found that fewer early EPC
colonies were produced in the CAD group (7.2 ± 3.l/well) than those in the control group (12.4 ± 1.4/well, 𝑝 < 0.05), and more late
EPC colonies were produced in the CAD group (0.8 ± 0.2/well) than those in the control group (0.25 ± 0.02/well, 𝑝 < 0.05). In
the CAD group, the relative expression of CD31 and KDR of early and late EPCs was lower than in the control group. These results
demonstrate that CAD patients could have increased late EPC density and that early and late EPCs in CAD patients exhibited
immature endothelial characteristics. We suggest that changes in EPC colony count and gene expression of endothelial markers
may have relation with development of CAD.
1. Introduction
Endothelial progenitor cells (EPCs) are of interest to med-
ical researchers because of their role in the pathogenesis
of atherosclerotic diseases such as coronary artery disease
(CAD) [1, 2]. Previous studies have shown that the number of
EPCs is related to vascular repair and endothelial restoration
and that EPC levels decrease in patients with diabetes
mellitus, hypertension, and CAD [2–4]. Recently, EPCs have
been obtained from mononuclear cells (MNCs) and studied
as two types of culture period-dependent cells. Early EPCs,
which produce colonies consisting of spindle-shaped cells
in the early period of culture (several days), have limited
proliferative capacity, and late EPCs, which produce colonies
in the later period of culture (3-4 weeks), have a distinctively
strong growth capacity [5–7].
EPCs can be considered as proliferative cells equipped
with endothelial property, and both EPC types express cell
surface markers specific to endothelial cells. However, EPCs
remain difficult to isolate from peripheral blood because
they are very rare in peripheral circulation, and therefore, a
definition for EPCs is not yet available [1, 5]. EPCs originate
from hemangioblast cells in the bone marrow and are differ-
entiated into endothelial cells. Circulating EPCs are recruited
to endothelial tissues suffering from hypoxia, and they attend
to blood vessel formation and repair in affected tissues [5].
They can be identified by cellular morphology, including
specific cell surface proteins, and by examining the expression
of genes encoding surface markers [8–10]. In this study,
we tested the hypothesis that endothelial dysfunction and
impaired endothelial repair in atherosclerotic disease are due
to impaired EPCs, which are disturbed during maturation
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and, thus, prevented from becoming mature and effective
EPCs. Specifically, we studied the characteristic features of
early and late EPCs in the presence or absence of CAD by
simultaneously examining colony formation in vitro and the
gene expression of specific surface markers.
2. Materials and Methods
2.1. Patients and Control Subjects. The local ethics committee
of the Kanazawa University Graduate School of Medicine
approved the use of human cells in this study, and informed
consent was obtained from all individual donors. All CAD
patients underwent a coronary angiography and exhibited
significant stenosis of the coronary arteries (significant steno-
sis was defined as >70% diameter stenosis, according to
AHA guidelines). Control subjects consisted of persons with-
out organic stenosis in their coronary arteries and healthy
volunteers free from clinical symptoms such as angina and
cardiovascular risk factors.
2.2. EPC Isolation and Culture. Circulating EPCs were iso-
lated from 30mL of heparinized peripheral blood collected
from donors. Briefly, MNCs were isolated using Ficoll-Paque
PLUS (GE Healthcare, Waukesha, USA) density gradient
centrifugation (400×g, 20∘C, 20min), washed twice with
phosphate-buffered saline (PBS), counted, and suspended in
PBS. MNCs from each donor were cultured separately in an
incubator on 6-well cell culture plates coated with fibronectin
(BD Biosciences, Heidelberg, Germany) at a density of 5 ×
106 cells/well.
Early EPCs and late EPCs were cultured according to the
following protocols.
For early EPCs, MNCs were cultured for 10 days in 𝛼-
MEM (Gibco-Life Technologies, Karlsruhe, Germany) with
20% fetal bovine serum (FBS) (Gibco-Life Technologies). For
late EPCs,MNCswere cultured for 28 days in complete EGM-
2 culture medium supplemented with EGM-2MV (Lonza,
Basel, Switzerland). The media were changed three times per
week [1, 11].
2.3. Enumeration of Early and Late EPC Colonies. The early
and late EPC colonies were counted using phase contrast
microscopy with a Diaphot microscope (Nikon, Tokyo,
Japan), according to the following methods. For early EPCs,
the number of colonies was counted in four randomly chosen
fields per well at ×40magnification; for late EPCs, all colonies
per well were counted [1]. As for variability of colony count,
intraobserver variability was <2.7% and interobserver one
was <5%.
2.4. Immunofluorescent Staining. Early and late EPC colonies
were prepared for the lectin binding and uptake studies
using the following methods. First, EPCs were incubated
with 1,1󸀠-dioctadecyl-3,3,3󸀠,3󸀠-tetramethyindocarbocyanide-
labeled acetylated low-density lipoprotein (Dil-Ac-LDL;
Biomedical Technologies Inc., Stoughton, USA) at 10 𝜇g/mL
in EGM-2 medium at 37∘C for 4 h. They were then washed
three times with PBS and fixed with 4% formaldehyde in PBS
for 20min at room temperature. Subsequently, the EPCswere
incubated with 200𝜇L of mouse anti-human UEA-1 (Ulex
lectin) antibody-conjugated with fluorescein isothiocyanate
(FITC) (Sigma, St. Louis, USA) at 4∘C for 1 h and thenwashed
three times with PBS.
Otherwise, early and late EPCs were washed twice with
PBS and fixed with 2% paraformaldehyde in PBS and then
incubated for 18 h at 4∘C in the dark with the following
antibodies: a phycoerythrin- (PE-) conjugated anti-human
CD34 antibody (BD Bioscience, USA), a FITC-conjugated
anti-humanCD45 antibody, and a PE-conjugated anti-kinase
domain receptor (KDR) antibody (R&D Systems, USA).
Stained colony dishes were observed with an immunofluo-
rescence microscope (Keyence, Osaka, Japan).
2.5. Quantitative Reverse Transcription-Polymerase Chain
Reaction (qRT-PCR). We measured the mRNA levels of
surface markers by using qRT-PCR. Adherent EPCs that
formed colonies were harvestedmechanically with cell scrap-
ers. Total RNA was extracted from the harvested EPCs
using the RNeasy Mini Kit (Qiagen, Venlo, Netherlands)
according to the manufacturer’s instructions. The extracted
RNA (500 ng) was subjected to cDNA synthesis using the
Super Script III First-Strand Synthesis System (Invitrogen,
CA, USA) in a final volume of 20 𝜇L. An ABI PRISM 7000
sequence detection system (Applied Biosystems, CA, USA)
was used to perform quantitative assessment of RNA levels.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was
used as a control for reactions. The primer sequences of
surface markers used for qRT-PCR were as follows: CD45
(forward, 5󸀠-TGGGACTGCTGAGAAGTGCA-3󸀠; reverse,




CCCTGGAAATCCT-3󸀠), and GAPDH (forward, 5󸀠-GGT-
GGTCTCCTCTGACTTCAACA-3󸀠; reverse, 5󸀠-GTGGTC-
GTTGAGGGCAATG-3󸀠). The results of qRT-PCR were
recorded as CT values (threshold cycle), which were defined
as the cycle number at which a fluorescent signal was
generated by SYBR Green I (Applied Biosystems, CA, USA).
In data analysis, the mRNA levels of a given gene were
evaluated by using the ΔΔCT method.
2.6. Statistical Analyses. Data were expressed as the mean ±
SEM. Data were analyzed by using ANOVA, with subsequent
comparisons by Student’s 𝑡-test. Statistical significance was
defined as 𝑝 < 0.05.
3. Results
3.1. Subject Profiles. The patient and control subject details
are shown in Table 1. Eighty-three individuals were enrolled
consisting of 47 patients withCADand 36 controls. Coronary
angiography was conducted in all of the CAD patients and 12
controls. Patients had various cardiovascular risk factors such
as diabetes, hypertension, and/or dyslipidemia and had been
administered medications corresponding to each disease.
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Table 1: Clinical background of examined subjects.
Parameters Control (𝑛 = 36) CAD (𝑛 = 47) 𝑝 value
Male gender 22 (61%) 34 (72%) n.s.
Age (years) 59 ± 14 67 ± 10 n.s.
Laboratory data
WBC (/𝜇L) 6710 ± 2654 5992 ± 1770 n.s.
Neutrophil (%) 61 ± 12 63 ± 8 n.s.
Lymphocyte (%) 30 ± 2 26 ± 9 n.s.
MDA-LDL/LDL-chol. 1.05 ± 0.02 1.27 ± 0.11 n.s.
hs-CRP (mg/dL) 0.10 ± 0.1 0.22 ± 0.3 n.s.
HbA1c (%) 5.6 ± 0.5 5.9 ± 0.7 n.s.
Disease
Diabetes mellitus 3 (8%) 14 (30%) <0.05
Hypertension 3 (8%) 21 (45%) <0.05
Hyperlipidemia 1 (3%) 20 (43%) <0.05
Medication
ARB or ACE-I 4 (11%) 22 (47%) <0.05
CCB 0 (0%) 14 (30%) <0.05
Statin 1 (3%) 20 (43%) <0.05
ACE = angiotensin converting enzyme, ARB = angiotensin receptor block-
age, CAD = coronary artery disease, and CCB = calcium channel blocker.
However, laboratory data showed that there were no signif-
icant differences in the levels of malondialdehyde-modified
low-density lipoprotein/low-density lipoprotein-cholesterol,
high sensitivity C-reactive protein, and hemoglobin A1c
between the CAD and control groups.
3.2. Morphology and Immunofluorescent Staining of Early
and Late EPC Colonies. Early EPC colonies characterized by
discrete cell aggregates were observed 4–6 days after MNCs
were initially seeded, and these colonies were counted 10 days
after seeding (Figure 1). Late EPC colonies were observed
approximately 2–4 weeks after seeding. First, small colonies
appeared, and then cells eventually proliferated to form a
monolayer tissue with cobblestone morphology similar to
that of the native endothelium (Figure 1). The late EPC
colonies were counted 28 days after seeding.
We stained EPC colonies with several antibodies to iden-
tify their characteristic surface markers. However, because
it is currently difficult to identify EPCs by staining with a
single surface marker, staining with a combination of surface
markers was necessary (e.g., the combination of CD34 and
KDR or FITC-UEA-1 lectin and uptake of Dil-Ac-LDL). As
described in a previous study [4], we examined colonies of
early and late EPCs that were double positive for stainingwith
UEA-1 lectin and Dil Ac-LDL (Figure 1).
Immunofluorescent staining by anti-CD34 and anti-KDR
antibody showed that early EPCs were positive for CD34 but
negative for KDR (Figure 2). Similarly, late EPCswere stained
positive for anti-CD34 and anti-KDR antibody. Importantly,
early EPCs were stained positive for leukocyte antigen CD45,
whereas late EPCs were stained negative (Figure 2). Based on
these immunoreaction results, a combination of the surface
markers was used to identify EPC types in the following
experiments.
3.3. Population Levels and Surface Markers of Early and
Late EPC Colonies. There were significantly fewer early EPC
colonies in the CAD group (7.2±3.1/well) than in the control
group (12.4 ± 1.4/well, 𝑝 < 0.05). In contrast, the average
number of late EPC colonies was higher in the CAD group
(0.8 ± 0.2/well) than in the control group (0.25 ± 0.02/well,
𝑝 < 0.05) (Figure 3). It was intriguing to examine early
and late EPCs in subset with 12 control subjects who had
coronary angiography. There were no differences in EPC
behavior between these subjects and the remaining control
subjects.
3.4. Evaluation of Gene Expression. Gene expression was
analyzed in both types of EPC by qRT-PCR. The mRNAs
of CD31, KDR, and CD45 were targeted; in general, CD31
and KDR are associated with endothelial lineage cells, and
CD45 is associated with hematopoietic lineage cells [2]. In
early EPCs, CD45 mRNA levels were significantly higher in
the CAD patient group than in the control group (𝑝 < 0.05);
however, CD31 and KDRmRNA levels tended to be higher in
the control group than in the CAD patient group (Figure 4).
In late EPCs, CD31 and KDR mRNA levels were higher in
the control group than the CAD group (1.0 versus 0.22 and
1.0 versus 0.51, resp.). In particular, CD31 mRNA levels were
significantly higher in the control group (𝑝 < 0.05). However,
expression of CD45 did not differ between the control and
CAD groups (1.0 versus 1.2) (Figure 5).
4. Discussion
In the present study, we demonstrate the following: (1) fewer
early EPC colonies were produced in patients with CAD than
in control subjects and higher late EPC colonies were found
in patients with CAD similarly; (2) in early EPCs, levels of
CD45 mRNA, which is a hematopoietic marker, were higher
in CAD patients than in control subjects; (3) in late EPCs,
the level of CD31 mRNA, which is an endothelial marker, was
lower in CAD patients than in control subjects.
Previous studies have shown that the number of early
EPC colonies decreases in patients exposed to cardiovascular
risk factors. In the present study, we investigated the behavior
of late EPC in addition to early EPC to find differences
between early EPCs and late EPCs in CADpatients compared
with control subjects, although it is still not clear whether the
origin of early and late EPCs was the same or not. However,
our results suggested at least that the quality, as well as the
quantity, of EPCs was an important factor in endothelial
repair and angiogenesis.
EPCs have been studied in conjunction with vascular
tissue architecture, function, and disease states. Our results
showed that both early and late EPCs presented surface
markers, such as CD34 and KDR, taking up Ac-LDL and
UEA-1 lectin, which were specific to endothelial cells [11,
12]. Differentiation from stem cells or progenitor cells to
mature cells has been well studied in many systems and
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Figure 1: Morphology and immunofluorescence staining of early and late EPCs. Upper panels show images of early EPCs and lower panels
show those of late EPCs. Left-hand panels show phase contrast microscopy images, middle panels show images of EPCs stained for Ulex







Figure 2: Immunofluorescence detection of anti-CD34, anti-KDR, and anti-CD45 antibodies. Immunofluorescence staining of early and late
EPCs is shown in the upper and lower panels, respectively. Left-hand, middle, and right-hand panels demonstrate staining for CD34, KDR,
and CD45, respectively. The original magnification was ×10.




































Figure 3: Mean number of observed early (a) and late (b) EPC colonies in control and CAD subjects. Early EPC colonies were counted on


























































Figure 4: Evaluation of gene expression in early EPCs by qRT-PCR. Relative quantification of surface markers CD45 (a), CD31 (b), and KDR
(c). ∗𝑝 < 0.05.
is characterized by a loss and gain of specific markers.
EPCs exhibit various steps of differentiation from premature
cells to mature cells. The proportion of expressed surface
markers, including CD34, KDR, and CD45, changes from
hematopoietic markers in immature cells to the endothelial
markers in mature cells [12–14]. EPCs that originate from
the hemangioblast in the bone marrow are released into
peripheral circulation, and then they adhere to the tissues
involved in repair of artery. Early EPCs emerge at an earlier
period of culture than late EPCs; thus, the characteristics of
early EPCs should be more similar to those of hematopoietic
cells than late EPCs [11]. In accordance with these findings,
our results showed that early EPCs were stained for CD45, a
hematopoietic marker, confirming the hematopoietic charac-
ter of early EPCs, which was similar to that of an immature
cell.
It has been proposed that the number of EPC colonies
is related to cardiovascular disease as with cerebrovascular
disease and pedal artery disease. For example, several studies
showed that the number of circulating early EPCs decreases


























































Figure 5: Evaluation of gene expression in late EPCs by qRT-PCR. Relative quantification of surface markers CD45 (a), CD31 (b), and KDR
(c). ∗𝑝 < 0.05.
in patients with diabetes, hypertension, and atherosclerosis
[15–17]. In our study, the cell density of early EPCs in CAD
patients was significantly lower than in control subjects.
A decrease in circulating EPCs may disturb angiogenesis
and is associated with a high risk of cardiovascular disease.
Patients with risk factors for ischemic cardiovascular disease
have fewer circulating EPCs, and that impaired migration of
EPCs is negatively correlated with cardiovascular risk factors.
In atherosclerotic diseases such as stroke and myocardial
infarction, which occur as the complications in diabetes
mellitus, hypertension, dyslipidemia, and so on, endothelial
dysfunction is caused by several factors that reduce the
viability and proliferation of EPCs and thereby increase
apoptosis of EPCs or decrease levels of endothelial nitric
oxide synthetase [18–21].
In this study, we focused on the relationship between the
maturity of EPCs and CAD associated with risk factors like
diabetesmellitus, hypertension, and dyslipidemia. Compared
with control subjects, patients with CAD showed higher
expression of the hematopoietic marker CD45 in early EPCs
and lower expression of the endothelial marker CD31. This
suggested that the peripheral circulating EPCs in CAD
patients were more characteristic to immature EPCs than
those in control subjects which consisted of at least subject
without defined CAD. Furthermore, the gene expression
profiles of both EPC types in CAD more closely resembled
those of primitive endothelial cells. Therefore, evaluating the
number of circulating immature EPCs, defined by surface
markers such as CD45 and CD31, may provide additional
insights into the mechanisms existing in the character of
EPCs in CAD patients.
EPCs recruited to disease sites may contribute to repair
and restore endothelial function.Therefore, it is important to
evaluate not only the number of EPC cells related to endothe-
lial formation and repair but also their quality. Specifically,
it is an important factor whether EPCs are released into
peripheral circulation before they mature into functional and
proliferative cells. Further work will be required to examine
how the maturity of EPCs affects the formation and repair
of the endothelium in peripheral arteries, and perhaps this
will need to include study of the tube formation. There
was a significant difference in medications in comparing
control and CAD subjects, thus impairing the present results.
However, previous studies suggested that the impact of these
medications on EPC behavior was minimized [6, 20].
There are some limitations in this study. First, the number
of subjects and the number of colonies of late EPCs were
relatively small; therefore, some group comparisons may lack
the power to detect significant differences between variables.
Second, the relationship between the EPC types and the
severity of angiographic CAD was not specified. Particularly,
it is of great interest to correlate severity of CAD and behavior
of EPCs clarifying this clinic-pathological relation. Finally,
no functional studies of endothelial function of the late EPC
were performed, although it would be important to know
if the late EPC functions were different when comparing
control and CAD subjects. Further functional study such as
migration, proliferation, and tube formation on Matrigel is
necessary to confirm the functional differences.
5. Conclusions
We examined the behavior of early and late EPCs in order
to understand the characteristics and roles of these EPCs in
CAD. On the basis of our results, we suggest that changes in
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EPC colony count and gene expression of endothelialmarkers
may have relation with development of CAD.
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